title: Stereospecific mobilization of intracellular Ca2+ by inositol 1,4,5-triphosphate. Comparison with inositol 1,4,5-trisphosphorothioate and inositol 1,3,4-trisphosphate.
abstract: The stereo specificity of myo-inositol 1,4,5-trisphosphate [Ins(1,4,5)P3] to mobilize Ca2+ from an intracellular store has been examined in permeabilized rat pituitary-tumour GH3 and Swiss 3T3 cells. A comparison of D-Ins(1,4,5)P3 with the synthetic enantiomer L-Ins(1,4,5)P3 and the racemate DL-Ins(1,4,5)P3 clearly demonstrates the marked stereospecificity of the response. Whereas D-Ins(1,4,5)P3 released 30-50% of non-mitochondrially-bound Ca2+ with a EC50 (concentration producing 50% of maximal response) of 200 nM, the L isomer was both substantially less potent and efficacious. A high concentration of the L isomer (10 microM) did not significantly shift the dose-response curve for the D isomer in Swiss 3T3 cells, suggesting that the less active isomer is probably a very weak agonist. Other studies revealed, in contrast with previous work, that the other naturally occurring isomer, D-Ins(1,3,4)P3, was essentially inactive in releasing Ca+, whereas a novel 5-phosphatase-resistant analogue, DL-myo-inositol 1,4,5-trisphosphorothioate, was a relatively potent full agonist in GH3 cells. These data reveal, for the first time, the stereoselectivity of the intracellular receptor associated with Ca2+ release. They also provide evidence for the activity of the novel phosphorothioate analogue of Ins(1,4,5)P3, but suggest that D-Ins(1,3,4)P3 is not involved in cellular Ca2+ mobilization.
authors.affiliation: Department of Pharmacology, University of Leicester, U.K.
authors.forename: J
authors.initials: J
authors.lastname: Strupish
authors.forename: A M
authors.initials: AM
authors.lastname: Cooke
authors.forename: B V
authors.initials: BV
authors.lastname: Potter
authors.forename: R
authors.initials: R
authors.lastname: Gigg
authors.forename: S R
authors.initials: SR
authors.lastname: Nahorski
mesh_terms: D002118:Calcium / Q000378:metabolism*; D002460:Cell Line; D004305:Dose-Response Relationship, Drug; D007294:Inositol / Q000031:analogs & derivatives* / Q000494:pharmacology; D015544:Inositol 1,4,5-Trisphosphate / Q000031:analogs & derivatives; D007295:Inositol Phosphates / Q000494:pharmacology*; D007424:Intracellular Fluid / Q000187:drug effects / Q000378:metabolism; D009946:Organothiophosphorus Compounds / Q000494:pharmacology*; D013237:Stereoisomerism; D013403:Sugar Phosphates / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
chemical_list: D007295:Inositol Phosphates; D009946:Organothiophosphorus Compounds; D013403:Sugar Phosphates; C054737:inositol 1,4,5-triphosphorothioate; D007294:Inositol; D015544:Inositol 1,4,5-Trisphosphate; D002118:Calcium